Ardelyx CEO Sells Shares, Stock Up 6.8% Y/Y
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Ardelyx CEO Michael Raab sold 41,666 shares, dropping his direct holdings to 1.8 million shares, but still leaving him with around 10.6 million dollars worth. This was part of his 10b5-1 trading plan, a routine move matching his trades over the last year and a half. Ardelyx focuses on gut and kidney meds, with their star drug tenapanor tackling constipation in IBS patients and phosphate issues in kidney disease. The stock closed at $5.84, with a market cap near $1.5 billion, though theyve been posting losses on $400 million in trailing revenue. The company recently onboarded a new chief medical officer and dropped a class action lawsuit, which could steer their pipeline forward. These sales are standard liquidity plays for execs, not red flags, especially with the stock up 6.8% year-over-year but down longer term.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/91ecefd8921ca1d3